跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 11,204 条关于
“Intercept Pharma”
全部
11,204
临床试验
5,590
药物
1,121
机构
1,225
资讯
3,268
去年
Intercept Pharmaceuticals Voluntarily Withdraws OCALIVA from US Market Following FDA Request
去年
Intercept Pharmaceuticals Withdraws Ocaliva from U.S. Market Following FDA Safety Directive
去年
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
去年
FDA Denies Full Approval for Ocaliva in Primary Biliary Cholangitis Treatment
去年
FDA Delays Decisions on Amgen's Lumakras and Intercept's Ocaliva
去年
FDA Rejects Full Approval of Obeticholic Acid for Primary Biliary Cholangitis
去年
FDA Delays Full Approval Decision for Alfagigma's Ocaliva Following Negative AdComm
6年前
FDA Rejects Intercept's NASH Drug Obeticholic Acid, Raising Industry-Wide Concerns
去年
Alcoholic Hepatitis Pipeline Insights 2024: Emerging Therapies and Market Prospects
去年
FDA Denies Full Approval for Ocaliva in Primary Biliary Cholangitis
第 1 页,共 327 页
上一页
下一页